Home / Market News / $EVO
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Evotec and Bristol Myers Squibb Receive Second IND Acceptance for Protein Degradation Candidate

Nov 19, 2026, 8:02 AM UTC · Primary ticker $EVO

Evotec and Bristol Myers Squibb received FDA acceptance for a second investigational new drug (IND) candidate, a cereblon E3 ligase modulator, under their protein degradation partnership. This marks a positive development for their collaboration, indicating progress in their drug development pipeline and potential future revenue streams.

Evotec and Bristol Myers Squibb announced FDA acceptance for a second investigational new drug (IND) candidate, a cereblon E3 ligase modulator, under their strategic protein degradation partnership. This is a significant milestone as it allows the drug to proceed to Phase 1 clinical trials, expected in 2027, following the first candidate which entered trials in March 2026. This development is positive for both companies, particularly Evotec, as it validates their drug discovery platform and strengthens their collaboration with a major pharmaceutical player. For traders, this indicates continued progress in their pipeline, offering long-term growth potential, though the immediate market impact might be moderate given the early stage of development and the 2027 trial start.

$EVO positive IND acceptance for partnered drug candidate
$BMY positive IND acceptance for partnered drug candidate
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.